Search filters

List of works by Ursula A. Matulonis

-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

scientific article

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

scientific article published on 12 December 2019

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).

scientific article published on 07 September 2016

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer

scientific article published on 2 November 2005

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer

scientific article

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

scientific article published on 10 July 2014

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

scientific article published in September 2002

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma ⬇️

scientific article published on August 9, 2012

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

scientific article published on December 2004

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer

scientific article

A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer.

scientific article

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

scientific article published on 23 December 2018

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer

scientific article published on 3 November 2017

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

scientific article published on 11 May 2020

A single-cell landscape of high-grade serous ovarian cancer

scientific article published on 22 June 2020

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance

scientific article published on 29 January 2015

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

scientific article published in October 2005

ACP Journal Club. Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer

scientific article published on September 2009

Abstract IA21: Combination treatments that include PI3K-inhibitors for the treatment of triple-negative breast cancer

Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients

scientific article published in June 2010

Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials.

scientific article published in January 2007

Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial

scientific article

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

scientific article published on 01 June 2019

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

scientific article published on 10 January 2019

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

scientific article published on 12 March 2020

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer

scientific article (publication date: 2012)

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model

scientific article published on 10 December 2015

Anti-angiogenic agents in ovarian cancer: dawn of a new era?

scientific article published on December 2011

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial

scientific article published on 10 October 2019

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)

scientific article published on 01 May 2019

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

scientific article published on 09 February 2016

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

scientific article

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor

scientific article published on 16 October 2017

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

scientific article published on 25 June 2020

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

scientific article published on 18 May 2020

Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

scientific article published on 17 April 2020

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer

scientific article published on 29 August 2018

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

scientific article published on 10 April 2017

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

scientific article published on 15 June 2020

Bevacizumab and Its Use in Epithelial Ovarian Cancer ⬇️

scientific article published on February 16, 2011

Bevacizumab in newly diagnosed ovarian cancer

scientific article published on 23 June 2015

Bevacizumab rechallenge after first line maintenance bevacizumab

scientific article published on 21 February 2012

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

scientific article published on 27 September 2016

Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study

scientific article published in April 2002

CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations ⬇️

scientific article published on October 13, 2010

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv

scientific article published on June 2015

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

scientific article published on 29 April 2020

Cancer of the ovary

scientific article published on 01 March 2005

Cancer- and Chemotherapy-Induced Anemia ⬇️

scientific article published on 01 May 2012

Cancer- and chemotherapy-induced anemia

scientific article

Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions

scientific article published on 01 November 2004

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

scientific article

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

scientific article published on 13 October 2009

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy

scientific article published on 12 February 2012

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine.

scientific article

Chemotherapy hypersensitivity reactions in ovarian cancer

scientific article published on March 2014

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

scientific article published on 17 October 2019

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

scientific article published on 6 January 2017

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

scientific article

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

article

Clinical assays for assessment of homologous recombination DNA repair deficiency

scientific article published on 01 October 2020

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival

scientific article published in January 2012

Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen

scientific article published on 6 November 2013

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

scientific article

Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type

scientific article published on 24 June 2020

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

scientific article published on 24 January 2019

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial

scientific article published on 05 August 2020

Comparison of the quality of life of early and advanced stage ovarian cancer survivors

scientific article published on 28 May 2009

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference

article

Current status and evolution of preclinical drug development models of epithelial ovarian cancer ⬇️

scientific article

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

scientific article published on 18 August 2020

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays

scientific article published on 19 October 2020

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer

scientific article published on 29 March 2019

Differential blood count as triage tool in evaluation of pelvic masses

scientific article published on 02 June 2020

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

scientific article

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

scientific article published on 22 June 2018

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

scientific article published on 21 August 2012

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

scientific article published on 09 January 2019

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

scientific article published on 06 August 2013

Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy

scientific article published in September 2004

Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer

scientific article published on 20 November 2020

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors

scientific article published on 22 June 2020

End of life issues in older patients

scientific article published on April 2004

Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer

scientific article published on 06 November 2020

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer

scientific article

Epithelial Ovarian Cancer ⬇️

scientific article published on 01 January 2011

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

scientific article published on 29 August 2016

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

scientific article published on 09 November 2018

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer

scientific article published on 08 May 2020

Genomic testing and precision medicine--What does this mean for gynecologic oncology?

scientific article published on 04 December 2015

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary

scientific article (publication date: 2011)

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary

scientific article published in August 2017

Hopelessness and Complementary Therapy Use in Patients With Ovarian Cancer ⬇️

scientific article published on July 1, 2013

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases

scientific article published on 27 May 2008

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

scientific article published on 19 March 2020

Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

scientific article published on 14 April 2019

Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer

scientific article

Influence of patients' preferences and treatment site on cancer patients' end-of-life care

scientific article published on October 2010

Institutional implementation of clinical tumor profiling on an unselected cancer population

scientific article published on 17 November 2016

Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials

scientific article

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

scientific article published on 21 February 2017

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer

scientific article published on December 2005

Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease

scientific article

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

scientific article published on 24 October 2018

Management of newly diagnosed or recurrent ovarian cancer

scientific article published on 01 June 2018

Management of the toxicities of common targeted therapeutics for gynecologic cancers

scientific article published on 30 January 2018

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance

scientific article

Metaplastic carcinoma of the breast with neuroglial differentiation

scientific article published on 25 October 2005

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas

scientific article published on 06 May 2016

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer

scientific article

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas

scientific article published in April 2018

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis

scientific article published on 24 September 2018

Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases

scientific article published on 05 August 2020

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

scientific article published on September 2011

NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer

scientific article

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

scientific article published on 18 December 2017

Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma

scientific article published on 12 June 2006

New Biologic Agents for the Treatment of Gynecologic Cancers ⬇️

scientific article published on February 1, 2012

New advances in ovarian cancer.

scientific article published on July 2010

New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances

scientific article

Next-Generation Sequencing: Role in Gynecologic Cancers

scientific article

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

scientific article published on 07 June 2019

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

scientific article

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

scientific article published on 16 September 2019

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

scientific article published on 01 April 2019

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

scientific article published on 27 March 2012

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

scientific article published on 14 March 2019

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

scientific article

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

scientific article published on 08 April 2016

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix

scientific article published on 23 August 2013

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer

scientific article published on 14 June 2019

Ovarian Cancer

scientific article published on 25 September 2018

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

scientific article published in September 2016

Ovarian Cancer, Version 3.2012 ⬇️

scientific article published on November 1, 2012

Ovarian cancer

scientific article published on 25 August 2016

Ovarian cancer clinical practice guidelines.

scientific article

Ovarian cancer, version 2.2013.

scientific article

Ovarian cancer. Clinical practice guidelines in oncology

scientific article published in October 2006

Ovarian cancer. Clinical practice guidelines in oncology

scientific article published on 01 September 2008

Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.

scientific article published in 2022

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

scientific article published on 08 September 2016

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival

scientific article

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

scientific article published on 01 December 2018

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

scientific article published on 25 July 2020

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey

scientific article published on 05 June 2018

PARP inhibitors in ovarian cancer: current status and future promise

scientific article published on 04 March 2014

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

scientific article

POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing.

scientific article published on 15 September 2014

Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course

scientific article published on 07 August 2019

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.

scientific article published on 25 April 2017

Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer

scientific article published on 29 June 2015

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies

scientific article

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer

scientific article published on 20 April 2010

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

scientific article published on 28 August 2019

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors

scientific article

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma ⬇️

scientific article published on July 5, 2012

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

scientific article published in November 2007

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer

scientific article published on 10 November 2008

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

scientific article published on 16 November 2009

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors

scientific article published in September 2003

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

scientific article published on 17 December 2014

Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors

scientific article published on 18 November 2009

Phase II trial of anastrozole in women with asymptomatic müllerian cancer

scientific article published on December 2003

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer

scientific article published on 12 November 2019

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

scientific article published on 27 December 2011

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

scientific article published on 18 February 2020

Photo quiz. Rash in a patient with ovarian cancer

scientific article published on 01 February 2012

Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health ⬇️

scientific article published on September 13, 2010

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.

scientific article published on 6 January 2016

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer

scientific article published on 28 August 2019

Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

scientific article published on 18 July 2018

Precision medicine

scientific article published on 01 April 2016

Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer

scientific article published on 06 November 2019

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

scientific article published on 13 September 2018

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients ⬇️

scientific article published on August 13, 2013

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy ⬇️

scientific article published on October 27, 2011

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome

scientific article

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma

scientific article published on 30 September 2009

Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy

scientific article published on 19 May 2016

Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.

scientific article published on 7 February 2018

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

scientific article published on 8 November 2016

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

scientific article published on 17 July 2018

Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments

scientific article

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor

scientific article

Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses

scientific article published on 27 July 2005

Rational use of cytotoxic chemotherapy for recurrent ovarian cancer

scientific article published on October 2006

Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

scientific article published on 20 October 2023

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer

scientific article published on 20 May 2019

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

scientific article published on 10 August 2019

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

scientific article published on 03 February 2020

Review: erythropoiesis-stimulating agents increase mortality in patients with cancer

scientific article published on December 2009

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions

scientific article published on 23 December 2015

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

scientific article published on 31 May 2022

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

scientific article published on 28 December 2016

Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.

scientific article

Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype

scientific article published in 2022

Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer ⬇️

scientific article published on 06 April 2012

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

scientific article published on 13 June 2019

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

scientific article

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.

scientific article published on 28 August 2017

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma

scientific article published on 08 November 2018

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer

scientific article published on 01 December 2018

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

scientific article published on 13 November 2018

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy ⬇️

scientific article published on September 27, 2012

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

scientific article published on 13 August 2019

The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial

scientific article published on December 2012

The NCI-MATCH trial and precision medicine in gynecologic cancers

scientific article published on 20 January 2018

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer

scientific article published on 3 June 2015

The importance of chemotherapy and radiation in uterine papillary serous carcinoma

scientific article published on 02 October 2011

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities

scientific article published on 31 January 2018

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib

scientific article published on 19 November 2019

Transforming ovarian cancer care by targeting minimal residual disease

scientific article published in November 2023

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

scientific article published on 18 December 2014

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations

scientific article

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

scientific article published on June 2005

Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels ⬇️

scientific article published on September 1, 2011

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer

scientific article

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer

scientific article

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

scientific article published on 21 July 2016

Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.

scientific article published on 21 December 2012

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

scientific article published on May 2016

Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples

scientific article

Young Women Diagnosed with Early-Stage Ovarian Cancer or Borderline Malignancy of the Ovary: A Focus on Fertility and Sexual Function ⬇️

scientific article published on 01 January 2012

β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers

scientific article published on 18 June 2014

Paulina is supported by:

About Paulina

Help